buc tissue microarray bl2081 Search Results


human bladder cancer tissue microarray bl208  (Biomax Inc)
90
Biomax Inc human bladder cancer tissue microarray bl208
Human Bladder Cancer Tissue Microarray Bl208, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human bladder cancer tissue microarray bl208/product/Biomax Inc
Average 90 stars, based on 1 article reviews
human bladder cancer tissue microarray bl208 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
tissue microarrays bl806  (Biomax Inc)
90
Biomax Inc tissue microarrays bl806
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
Tissue Microarrays Bl806, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tissue microarrays bl806/product/Biomax Inc
Average 90 stars, based on 1 article reviews
tissue microarrays bl806 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
tissue microarrays (tma  (TissueArray.com LLC)
90
TissueArray.com LLC tissue microarrays (tma
EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays <t>BL2081</t> and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.
Tissue Microarrays (Tma, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tissue microarrays (tma/product/TissueArray.com LLC
Average 90 stars, based on 1 article reviews
tissue microarrays (tma - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.

Journal: Scientific Reports

Article Title: Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)

doi: 10.1038/s41598-019-38575-x

Figure Lengend Snippet: EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression. 232 BC samples were stained, and 186 (80%) samples showed presence of either EGFR, HER2, or both. Of those, 79 (42.4%) samples and 23 (12.4%) showed only EGFR expression and only HER2 expression, respectively. 84 (45.2%) samples showed co-expression of EGFR and HER2.

Article Snippet: Figure 1 EGFR and HER2 expression in bladder cancer. ( A ) TCGA dataset was used to show increased expression of EGFR and HER2 in bladder cancer. (i) EGFR is significantly elevated in bladder cancer compared to normal urothelium ( P < 0.01; ANOVA), specifically in ‘basal’ subtype classes 3 and 4. (ii) HER2 is significantly elevated in bladder cancer compared to the normal urothelium ( P < 0.01; ANOVA), specifically in ‘luminal’ subtype classes 1 and 2. ( B ) Tissue microarrays BL2081 and BL806 (Biomax) were analyzed for the presence of EGFR and HER2 expression.

Techniques: Expressing, Staining